<DOC>
	<DOCNO>NCT01019837</DOCNO>
	<brief_summary>The spread Influenza H1N1 prompt development vaccine virus . IBD patient increase risk develop complication Influenza H1N1 . The efficacy safety H1N1 vaccination evaluate population patient . We would like estimate efficacy safety vaccination influenza H1N1 patient IBD treat immunomodulatory drug .</brief_summary>
	<brief_title>Efficacy Safety Vaccination Against Influenza H1N1 Patients With Inflammatory Bowel Diseases ( IBD ) Treated Immunomodulators Biologics</brief_title>
	<detailed_description>200 patient IBD 200 healthy subject participate study . All subject vaccinate Focetria ( Novartis ) evaluate day vaccination 4 week later . The evaluation include : Efficacy vaccine : Blood drawn day 0 4 week later test presence antibody A/California17/2009/H1N1 hemagglutination inhibition test . Safety vaccine : - Records adverse event - Assessment disease activity : CDAI MAYO score</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>1 . Patients suffer IBD ( inflammatory bowel disease ) : UC/ CD 2 . Able firm inform consent 3 . Aged 1865 4 . Candidates receive vaccination H1N1 , accord recommendation Ministry Health 5. patient treated immunomodulators biologics 1 . Allergy egg 2 . Known allergy seasonal influenza vaccine 3 . Pregnant woman 4 . Patients inoculate another vaccine past 3 week ( except vaccine fot seasonal influenza 5 . Patients without worsen disease condition ( stable condition )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Vaccine</keyword>
</DOC>